Compare · DXCM vs PRCT
DXCM vs PRCT
Side-by-side comparison of DexCom Inc. (DXCM) and PROCEPT BioRobotics Corporation (PRCT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and PRCT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.85B, about 17.4x PRCT ($1.66B).
- Over the past year, DXCM is down 10.0% and PRCT is down 53.2% - DXCM leads by 43.1 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 16 for PRCT).
- Both have 25 recent analyst ratings on file.
- Company
- DexCom Inc.
- PROCEPT BioRobotics Corporation
- Price
- $74.78-4.36%
- $29.11+1.11%
- Market cap
- $28.85B
- $1.66B
- 1M return
- +26.00%
- +9.95%
- 1Y return
- -10.02%
- -53.15%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 26
- 16
- Recent ratings
- 25
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest PRCT
- PROCEPT BioRobotics downgraded by Leerink Partners with a new price target
- Director Desai Antal Rohit was granted 3,315 shares, increasing direct ownership by 9% to 38,467 units (SEC Form 4)
- Director Dodrill Amy M. was granted 3,315 shares, increasing direct ownership by 43% to 10,941 units (SEC Form 4)
- Director Garrett Mary was granted 3,315 shares, increasing direct ownership by 23% to 17,700 units (SEC Form 4)
- Director Harris Taylor C. was granted 3,315 shares, increasing direct ownership by 3% to 102,491 units (SEC Form 4)
- Director Little Elisabeth Sandoval was granted 3,315 shares, increasing direct ownership by 26% to 15,876 units (SEC Form 4)
- Director Moll Frederic H was granted 3,315 shares, increasing direct ownership by 0.38% to 866,474 units (SEC Form 4)
- Director Prescott Thomas M was granted 3,315 shares, increasing direct ownership by 85% to 7,211 units (SEC Form 4)
- Director Puckett Dan was granted 3,315 shares, increasing direct ownership by 61% to 8,791 units (SEC Form 4)
- PROCEPT BioRobotics Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders